Using human non-small cell lung cancer (NSCLC) cells, Sun et al. reported that mTOR inhibition by rapamycin induces activation of survival pathways involving increase of Akt and eIF4E phosphorylation. Here, EIF4E is linked to non-small cell lung carcinoma.